<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Blood management and anticoagulation for cardiopulmonary bypass
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Blood management and anticoagulation for cardiopulmonary bypass
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Blood management and anticoagulation for cardiopulmonary bypass
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kamrouz Ghadimi, MD, MHSc, FAHA
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ian J Welsby, BSc, MBBS, FRCA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan B Mark, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nancy A Nussmeier, MD, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 16, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1359776482">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Blood and coagulation management are key components of anesthetic management for cardiac surgical procedures that require cardiopulmonary bypass (CPB) because of the need for full systemic anticoagulation during CPB with reversal after weaning from CPB, hemodilution due to fluid priming of the extracorporeal circuit, as well as fibrinolysis, platelet dysfunction, coagulation factor consumption, and systemic hypothermia that occur during CPB, and the likelihood of blood loss during surgery involving the heart and great vessels [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         This topic discusses systemic anticoagulation in preparation for initiation of CPB, and strategies to avoid or minimize blood loss and transfusion of blood products before and during CPB. After weaning from CPB, protamine administration to reverse systemic heparin anticoagulation and management of postbypass bleeding are discussed in separate topics. (See
         <a class="medical medical_review" href="/z/d/html/140293.html" rel="external">
          "Protamine: Administration and management of adverse reactions during cardiovascular procedures", section on 'Protamine administration after cardiopulmonary bypass'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/122792.html" rel="external">
          "Achieving hemostasis after cardiac surgery with cardiopulmonary bypass"
         </a>
         .)
        </p>
        <p>
         General principles for perioperative blood management are discussed in separate topics. (See
         <a class="medical medical_review" href="/z/d/html/94347.html" rel="external">
          "Perioperative blood management: Strategies to minimize transfusions"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112610.html" rel="external">
          "Intraoperative transfusion and administration of clotting factors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3285605004">
         <span class="h1">
          EFFECTS OF CARDIOPULMONARY BYPASS ON HEMOSTASIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiopulmonary bypass (CPB) is a complex pathophysiologic state that induces several hemostatic changes  (
         <a class="graphic graphic_figure graphicRef120782" href="/z/d/graphic/120782.html" rel="external">
          figure 1
         </a>
         ). Contact of blood with nonendothelial surfaces of the CPB circuit induces an intense inflammatory response due to the exposure to procoagulant substances, which results in coagulopathy due to platelet activation and dysfunction, initiation of the coagulation cascade, and decreased levels of circulating coagulation factors [
         <a href="#rid3">
          3-5
         </a>
         ]. Thrombin generation and activation of fibrinolytic pathways result in consumption of platelets and pro- and anticoagulant proteins (especially fibrinogen and antithrombin) [
         <a href="#rid6">
          6-9
         </a>
         ].
        </p>
        <p>
         Furthermore, the priming solution for the CPB circuit (typically 1 to 1.5 L of a balanced crystalloid solution) results in hemodilution that exacerbates anemia and may also worsen coagulopathy and bleeding (see
         <a class="local">
          'Strategies to minimize further hemodilution'
         </a>
         below). Typical laboratory findings immediately after CPB include decreased platelet count, low fibrinogen, and increased prothrombin time (PT), activated partial thromboplastin time (aPTT), and D-dimer levels. Postbypass hypothermia may worsen coagulopathy. (See
         <a class="medical medical_review" href="/z/d/html/122792.html" rel="external">
          "Achieving hemostasis after cardiac surgery with cardiopulmonary bypass", section on 'Maintenance of normothermia'
         </a>
         .)
        </p>
        <p>
         Due to these effects on hemostasis, successful perioperative blood management strategies can reduce transfusions during cardiac surgery with CPB, although some patients may benefit more than others from this approach [
         <a href="#rid10">
          10-13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2407873720">
         <span class="h1">
          MANAGEMENT BEFORE CARDIOPULMONARY BYPASS
         </span>
        </p>
        <p class="headingAnchor" id="H2974393964">
         <span class="h2">
          Blood conservation strategies
         </span>
        </p>
        <p class="headingAnchor" id="H1255872932">
         <span class="h3">
          Intraoperative blood salvage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intraoperative blood salvage is used before and after CPB for most cardiac surgical procedures due to the high likelihood of significant blood loss (&gt;1000 mL), based on evidence that allogeneic blood transfusion and its associated complications can be avoided with a very low incidence of adverse events. Intraoperative blood salvage may also be acceptable to some Jehovah's Witnesses who will not accept allogeneic blood [
         <a href="#rid14">
          14
         </a>
         ]. Details regarding this technique and the evidence supporting its administration are available in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/7937.html" rel="external">
          "Surgical blood conservation: Intraoperative blood salvage"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3961973660">
         <span class="h3">
          Acute normovolemic hemodilution
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute normovolemic hemodilution (ANH) is used before CPB in selected patients [
         <a href="#rid15">
          15
         </a>
         ]. This technique involves removal of blood from a patient shortly after induction of anesthesia, with maintenance of normovolemia using crystalloid and/or colloid replacement. Factors influencing the decision to use ANH include a preoperative hemoglobin (Hb) &gt;13 g/dL, patient size, hemodynamic stability during the prebypass period, and absence of coagulopathy or significant prebypass bleeding (eg, due to redo sternotomy). It is a good option for Jehovah's Witnesses since many will consent to ANH if their blood is maintained in a closed circuit continuous flow system [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7927.html" rel="external">
          "Approach to the patient who declines blood transfusion"
         </a>
         .)
        </p>
        <p>
         The amount of blood removed during ANH typically varies between 1 and 3 units (450 to 500 mL constitutes 1 unit), and is calculated based on the patient's estimated blood volume, initial Hb level, and desired Hb level after withdrawal of blood with hemodilution (see
         <a class="medical medical_review" href="/z/d/html/7936.html" rel="external">
          "Surgical blood conservation: Acute normovolemic hemodilution", section on 'Amount of blood to withdraw'
         </a>
         ). This technique decreases Hb concentration during the period when most surgical blood loss is occurring, thereby minimizing the effects of red blood cell (RBC) losses, while allowing reinfusion of the patient's own fresh whole blood (which includes RBCs, viable platelets, and high levels of clotting factors) during or shortly after the surgical procedure. Further details regarding the ANH technique are available in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/7936.html" rel="external">
          "Surgical blood conservation: Acute normovolemic hemodilution"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2017 meta-analysis of 29 randomized trials that included more than 2400 cardiac surgical patients noted a lower incidence of allogeneic transfusion in the ANH group (42 versus 56 percent), with the number of transfused units reduced by approximately 1 unit compared with usual care [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a national registry that included more than 18,000 adult cardiac surgical patients, use of ANH resulted in a lower intraoperative transfusion rates (10 percent with or 8 percent without an autologous priming [AP] blood conservation technique), compared with patients who had no blood conservation technique (27 percent were transfused) or those who had only an AP technique (20 percent were transfused) [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="local">
          'Autologous priming techniques'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3903466626">
         <span class="h3">
          Avoiding excessive fluid administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients who do not undergo ANH, fluid administration prior to CPB is typically restricted to the relatively small volumes necessary to administer intravenous (IV) medications because hemodilution will occur at onset of CPB as the patient's blood volume intermixes with 1.0 to 1.5 L crystalloid CPB prime. (See
         <a class="medical medical_review" href="/z/d/html/126473.html" rel="external">
          "Anesthesia for cardiac surgery: General principles", section on 'Prebypass fluid management'
         </a>
         .)
        </p>
        <p>
         Exceptions include patients with signs of hypovolemia and those who are undergoing ANH. (See
         <a class="local">
          'Acute normovolemic hemodilution'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H25221848">
         <span class="h2">
          Systemic anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic anticoagulation is necessary before initiation of CPB. Typically this is accomplished with a bolus dose of heparin administered before aortic cannulation for initiation of CPB [
         <a href="#rid19">
          19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/115759.html" rel="external">
          "Initiation of cardiopulmonary bypass", section on 'Aortic cannulation'
         </a>
         .)
        </p>
        <p>
         In rare instances of drug shortages, multiuse vials may be the only source of heparin [
         <a href="#rid20">
          20,21
         </a>
         ]. In these circumstances, hospital pharmacies may use a single medication vial to prepare multiple syringes under sterile conditions for use in multiple patients. (See
         <a class="medical medical_review" href="/z/d/html/94596.html" rel="external">
          "Prevention of perioperative medication errors", section on 'Avoid multiuse vials'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H163908497">
         <span class="h3">
          Heparin administration and monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         The IV dose of heparin administered in preparation for CPB is typically 300 to 400 units/kg, with confirmation of adequacy of systemic anticoagulation so that clot formation in the CPB circuit will be prevented [
         <a href="#rid14">
          14,22,23
         </a>
         ]. In obese patients undergoing CPB, basing the initial heparin dose on ideal rather than total body weight is reasonable, as long as adequate anticoagulation is verified [
         <a href="#rid24">
          24,25
         </a>
         ].
        </p>
        <p>
         Adequacy of anticoagulation after heparin administration is measured using a point-of-care test that measures the activated whole blood clotting time (ACT) to achieve a targeted value. Blood sampling for ACT testing is performed approximately three minutes after heparin administration. A minimum post-heparin ACT value ≥400 to 480 seconds is targeted before initiation of CPB, although evidence defining optimal ACT is lacking [
         <a href="#rid22">
          22,26-29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">
          "Clinical use of coagulation tests", section on 'Monitoring heparins'
         </a>
         .)
        </p>
        <p>
         Advantages of heparin anticoagulation include the ability to rapidly titrate its anticoagulant effect and rapidly reverse this effect with
         <a class="drug drug_general" data-topicid="9831" href="/z/d/drug information/9831.html" rel="external">
          protamine sulfate
         </a>
         . Other advantages include clinician familiarity due to decades of use and low cost compared with alternatives such as direct thrombin inhibitors.
        </p>
        <p>
         However, management of systemic anticoagulation in patients with heparin resistance or heparin-induced thrombocytopenia (HIT) can be challenging, as discussed in the sections below. (See
         <a class="local">
          'Heparin resistance'
         </a>
         below and
         <a class="local">
          'Heparin-induced thrombocytopenia (HIT)'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H347376502">
         <span class="h3">
          Heparin resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         The term "heparin resistance" is used when the desired preset anticoagulation goal (typically an ACT target value ≥400 to 480 seconds) is not achieved after administration of a standard initial heparin dose  (
         <a class="graphic graphic_algorithm graphicRef110924" href="/z/d/graphic/110924.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid28">
          28,30
         </a>
         ].
        </p>
        <p>
         Approximately 5 percent of cardiac surgical patients are resistant to heparin by one of several mechanisms (eg, preoperative infusions of heparin, liver insufficiency, elevated fibrinogen levels) [
         <a href="#rid31">
          31
         </a>
         ]. Since heparin acts by binding to its cofactor antithrombin (AT; previously called antithrombin III [ATIII]), deficiency of this cofactor is often the cause of inadequate heparin anticoagulation [
         <a href="#rid15">
          15,28,32
         </a>
         ]. AT levels &lt;50 percent are often observed in cardiac surgical patients [
         <a href="#rid33">
          33,34
         </a>
         ]. However, unless AT concentration was measured in the preoperative period, the diagnosis of AT deficiency as the cause of unanticipated heparin resistance cannot be certain. In this situation, it is reasonable to administer additional heparin doses, although an upper limit of heparin dose has not been determined  (
         <a class="graphic graphic_algorithm graphicRef110924" href="/z/d/graphic/110924.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid28">
          28,35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">
          "Heparin and LMW heparin: Dosing and adverse effects", section on 'Heparin resistance/antithrombin deficiency'
         </a>
         .)
        </p>
        <p>
         If additional heparin dosing up to a total of 600 units/kg does not achieve the ACT target, and other potential causes have been considered, we administer AT concentrate 500 to 1000 units (if available) [
         <a href="#rid15">
          15,32,36-41
         </a>
         ], or Fresh Frozen Plasma (FFP) 2 to 4 units [
         <a href="#rid22">
          22,23,28
         </a>
         ], in patients who have known or suspected AT deficiency  (
         <a class="graphic graphic_algorithm graphicRef110924" href="/z/d/graphic/110924.html" rel="external">
          algorithm 1
         </a>
         ). Administration of AT concentrate rather than FFP is preferred for patients with heparin resistance since AT concentrate does not result in volume overload and there is less risk of infection transmission and other complications of blood transfusion [
         <a href="#rid15">
          15,36,37,42
         </a>
         ]. ACT measurements are then repeated. Plasma heparin concentrations determined by point-of-care assays such as heparin-protamine titration, if available, provide supplemental information [
         <a href="#rid22">
          22
         </a>
         ]. For example, if a total dose of 600 units/kg of heparin has been administered and plasma heparin concentration is ≥4 units/mL, initiation of CPB is a reasonable strategy since this appears to be the critical concentration of heparin required to prevent thrombosis during CPB  (
         <a class="graphic graphic_algorithm graphicRef110924" href="/z/d/graphic/110924.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid28">
          28,32,43,44
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1360.html" rel="external">
          "Antithrombin deficiency", section on 'Available AT products and dosing'
         </a>
         .)
        </p>
        <p>
         The effect of AT supplementation on clinically meaningful outcomes in adults is under investigation. In pediatric cardiac surgery, normalization of AT level results in reduced coagulopathy and bleeding, while the effect on postoperative thrombotic complications is unclear [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         Causes of heparin resistance other than AT deficiency (eg, thrombocytosis, elevated factor VIII concentration, elevated fibrinogen concentration) are often mitigated by the hemodilution that occurs after onset of CPB (see
         <a class="local">
          'Strategies to minimize further hemodilution'
         </a>
         below). Rarely, a lower ACT value of approximately 350 seconds may be accepted for initiation of CPB in a patient with heparin resistance [
         <a href="#rid26">
          26
         </a>
         ], with administration of additional heparin by a fixed dosing regimen (eg, heparin 100 to 150 units/kg per hour, or 50 units/kg every 30 minutes if the duration of CPB will be brief)  (
         <a class="graphic graphic_algorithm graphicRef110924" href="/z/d/graphic/110924.html" rel="external">
          algorithm 1
         </a>
         ). However, since failure to maintain therapeutic heparin levels has been associated with coagulopathic bleeding due to consumption of clotting factors by a process analogous to low grade disseminated intravascular coagulation, consultation with the surgeon and perfusionist regarding this management strategy is necessary [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         Although there is no upper limit for heparin dosing, large doses will accumulate in body tissues. Subsequently, gradual release of heparin into the intravascular space may occur, typically after CPB has been terminated and protamine has been administered to neutralize heparin effect. This possibility of significant residual anticoagulation due to "heparin rebound" is preemptively treated by administering a protamine infusion at 25 mg/hour, beginning after initial reversal of heparin anticoagulation, and extending into the postoperative period over approximately four hours. (See
         <a class="medical medical_review" href="/z/d/html/140293.html" rel="external">
          "Protamine: Administration and management of adverse reactions during cardiovascular procedures", section on 'Avoiding heparin rebound'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H210693530">
         <span class="h3">
          Heparin-induced thrombocytopenia (HIT)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Occasionally, a patient presents for cardiac surgery with a current or remote history of heparin-induced thrombocytopenia (HIT)  (
         <a class="graphic graphic_algorithm graphicRef118879" href="/z/d/graphic/118879.html" rel="external">
          algorithm 2
         </a>
         ) [
         <a href="#rid46">
          46
         </a>
         ]. If HIT antibodies are present, surgery is delayed if possible. For urgent or emergency cardiac surgery, protocols for use of
         <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">
          bivalirudin
         </a>
         with or without CPB have been established  (
         <a class="graphic graphic_table graphicRef108174" href="/z/d/graphic/108174.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid22">
          22,47-51
         </a>
         ]. Other strategies have also been used, including plasmapheresis prior to surgery, administration of intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) prior to heparinization, use of an intravenous direct thrombin inhibitor (eg, bivalirudin), or coadministration of
         <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">
          epoprostenol
         </a>
         with heparin. Management of these patients is discussed in detail in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/118004.html" rel="external">
          "Management of heparin-induced thrombocytopenia (HIT) during cardiac or vascular surgery"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4240340797">
         <span class="h2">
          Antifibrinolytic administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since fibrinolysis is a major contributor to coagulopathy and bleeding during cardiac surgery with CPB, we recommend administration of prophylactic antifibrinolytic therapy (either epsilon-aminocaproic acid [EACA] or
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         [TXA])  (
         <a class="graphic graphic_figure graphicRef120782" href="/z/d/graphic/120782.html" rel="external">
          figure 1
         </a>
         ). Details regarding dosing, timing of administration, and efficacy are presented in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/140949.html" rel="external">
          "Intraoperative use of antifibrinolytic agents", section on 'Use of antifibrinolytic agents in cardiac surgery'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1442494378">
         <span class="h1">
          MANAGEMENT DURING CARDIOPULMONARY BYPASS
         </span>
        </p>
        <p class="headingAnchor" id="H1305198798">
         <span class="h2">
          Strategies to minimize further hemodilution
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiac surgical patients often arrive to the operating room with anemia (see
         <a class="medical medical_review" href="/z/d/html/94291.html" rel="external">
          "Preoperative evaluation for anesthesia for cardiac surgery", section on 'Anemia'
         </a>
         ). Excessive fluid administration and hemodilution before cardiopulmonary bypass (CPB) exacerbates preexisting anemia. (See
         <a class="local">
          'Avoiding excessive fluid administration'
         </a>
         above.)
        </p>
        <p>
         During onset of CPB, further hemodilution occurs as the patient's own blood volume intermixes with the volume of crystalloid in the CPB prime (as much as 1.5 L) [
         <a href="#rid52">
          52
         </a>
         ]. These factors increase the risk of meeting a threshold for transfusion of red blood cells (RBCs). (See
         <a class="local">
          'Management of anemia'
         </a>
         below.)
        </p>
        <p>
         Strategies to minimize hemodilution during CPB may maintain hemoglobin (Hb) levels above transfusion thresholds and avoid the need for transfusion, as discussed in this section. However, safe use of such blood conservation techniques requires adequate prebypass oxygen carrying capacity and intravascular volume status.
        </p>
        <p class="headingAnchor" id="H2442633183">
         <span class="h3">
          Minimizing circuit prime volume
         </span>
         <span class="headingEndMark">
          —
         </span>
         Typically, initiation of CPB with a crystalloid priming solution reduces Hb concentration by 1 to 2 g/dL due to hemodilution occurring as the patient’s blood volume intermixes with 1.0 to 1.5 L of crystalloid CPB prime. Excessive hemodilution may occur if the CPB circuit volume is large or if patient blood volume is limited by small patient size. Selection of a CPB circuit of appropriate size minimizes circuit prime volume and reduces risk for excessive hemodilution [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H117490812">
         <span class="h3">
          Autologous priming techniques
         </span>
         <span class="headingEndMark">
          —
         </span>
         Techniques such retrograde autologous priming (RAP) and/or venous antegrade priming (VAP) are used in many institutions to prime the CPB circuit, thereby allowing reduction of the crystalloid priming volume and decreasing the degree of hemodilution [
         <a href="#rid15">
          15
         </a>
         ]. Either a RAP or a VAP technique allows expulsion of 400 to 800 mL of crystalloid prime, thereby minimizing hemodilution. In a 2021 meta-analysis in cardiac surgical patients that included 11 randomized trials (1337 participants) and 10 observational studies (2327 patients), RAP was associated with a reduced overall incidence of RBC transfusions (odds ratio [OR] 0.34, 95% CI 0.22-0.550) compared with patients not receiving RAP, while incidences of stroke or acute kidney injury (AKI) were similar [
         <a href="#rid53">
          53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/115759.html" rel="external">
          "Initiation of cardiopulmonary bypass", section on 'Autologous priming'
         </a>
         .)
        </p>
        <p>
         Success of a RAP and/or VAP approach depends on patient size and prebypass intravascular volume status, as well as the prime circuit volume. Pre-existing patient hypovolemia limits the clinicians' ability to safely perform RAP with or without VAP. Furthermore, hypovolemia can be induced as RAP progresses. To avoid organ hypoperfusion with potential consequences such as stroke or AKI, the anesthesiologist and perfusionist must recognize hypovolemia during initiation of CPB, and treat this by infusing either available blood previously salvaged from the surgical field, blood previously harvested during normovolemic hemodilution, or other fluid for volume replacement. (See
         <a class="medical medical_review" href="/z/d/html/7937.html" rel="external">
          "Surgical blood conservation: Intraoperative blood salvage"
         </a>
         and
         <a class="local">
          'Acute normovolemic hemodilution'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1300032468">
         <span class="h3">
          Ultrafiltration techniques
         </span>
         <span class="headingEndMark">
          —
         </span>
         Zero-balance ultrafiltration (UF) techniques can be used to prevent further hemodilution after the initial decrease in Hb level at onset of CPB, and to subsequently remove additional accumulated volume after administration of cardioplegia solution [
         <a href="#rid14">
          14,15
         </a>
         ]. However, the authors do not recommend the routine use of negative balance UF during CPB to attempt to "reverse" hemodilution in favor of a higher hematocrit (Hct), as there has been an association with AKI [
         <a href="#rid54">
          54,55
         </a>
         ].
        </p>
        <p>
         Conventional UF employs a hemofiltration filter in parallel to the CPB circuit that can continuously remove plasma-free solute and water from diverted blood, thereby concentrating Hb levels, and possibly removing inflammatory mediators [
         <a href="#rid56">
          56
         </a>
         ], or small molecules such as potassium [
         <a href="#rid57">
          57
         </a>
         ]. In one multicenter trial performed in patients undergoing coronary artery bypass grafting (CABG) surgery, conventional UF used during CPB in 1362 patients increased risk of acute kidney injury (AKI) compared with 5045 patients who did not have UF [
         <a href="#rid58">
          58
         </a>
         ]. The investigators emphasized the importance of avoiding excessive filtration that may result in induced hypovolemia.
        </p>
        <p class="headingAnchor" id="H3752368875">
         <span class="h2">
          Management of anemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         For Hb &lt;7.5 g/dL (or Hct &lt;22 percent), initial treatment during CPB is removal of fluid by ultrafiltration (hemoconcentration), if volume status allows, to account for hemodilution due to the CPB prime [
         <a href="#rid59">
          59
         </a>
         ] (see
         <a class="local">
          'Ultrafiltration techniques'
         </a>
         above). One retrospective analysis of more than 1600 adult cardiac surgery patients without baseline kidney disease from a single academic medical center suggested that high-volume conventional ultrafiltration (CUF) &gt;32 mL/kg was associated with AKI [
         <a href="#rid55">
          55
         </a>
         ]. However, a systemic review and meta-analysis of more than 8000 patients did not show any increased risk for kidney injury even with high-volume CUF [
         <a href="#rid60">
          60
         </a>
         ]. Furthermore, subgroup analysis of those with previous renal insufficiency suggested no significance differences in incremental AKI development (RR = 0.84, 95% CI, 0.53-1.33, p = 0.47). Nevertheless, in the absence of evidence from randomized controlled trials, large-volume CUF should be used cautiously, particularly in patients at risk for AKI [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         If further treatment for severe anemia or hypovolemia is necessary, available salvaged blood is returned first, followed by reinfusion of blood units harvested via normovolemic hemodilution, and then if needed, administration of allogeneic RBCs. (See
         <a class="medical medical_review" href="/z/d/html/7937.html" rel="external">
          "Surgical blood conservation: Intraoperative blood salvage"
         </a>
         and
         <a class="local">
          'Acute normovolemic hemodilution'
         </a>
         above.)
        </p>
        <p>
         Transfusion of allogeneic RBCs is reasonable if Hb remains &lt;7.5 g/dL when hemoconcentration is not possible or is ineffective, and neither salvaged nor harvested blood is available [
         <a href="#rid61">
          61-63
         </a>
         ]. Leukocyte-reduced blood is preferred [
         <a href="#rid64">
          64
         </a>
         ]. However, the optimal Hb level during cardiac surgery is not known. Thus, transfusion decisions are individualized, taking into account patient-related factors (eg, age, severity of illness, cardiac function, risk for critical end-organ ischemia), the clinical setting (massive or active blood loss, the operation being performed), and clinical or laboratory parameters indicating hypoperfusion (eg, metabolic acidosis, lactic acidosis, SvO
         <sub>
          2
         </sub>
         &lt;60 percent) [
         <a href="#rid36">
          36,65,66
         </a>
         ].
        </p>
        <p>
         Guidelines published by professional societies recommend RBC transfusion for Hb &lt;6 g/dL, but also recommend avoiding red cell transfusion for Hb &gt;10 g/dL [
         <a href="#rid14">
          14,36
         </a>
         ]. Both transfusion of RBCs and very low nadir Hb levels &lt;6 to 7 g/dL during CPB are associated with increased morbidity and mortality [
         <a href="#rid59">
          59,65,67-71
         </a>
         ]. In particular, nadir Hct during CPB has been associated with postoperative AKI [
         <a href="#rid70">
          70,72-81
         </a>
         ]. Although decline in postoperative renal function may be attributable to adverse effects of reduced oxygen delivery due to anemia during CPB, no critical Hb threshold predicting AKI has been identified. Notably, RBC transfusion during cardiac surgery is also associated with AKI [
         <a href="#rid72">
          72,78,81,82
         </a>
         ]. Furthermore, unnecessary transfusion of blood products in patients who are normovolemic and hemodynamically stable may also have adverse consequences such as transfusion-associated circulatory overload (TACO) [
         <a href="#rid83">
          83
         </a>
         ]. Details regarding evidence supporting decisions to withhold or transfuse RBCs during cardiac surgery are available in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">
          "Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Cardiac surgery'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2478253365">
         <span class="h2">
          Maintenance of anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maintenance of heparin anticoagulation throughout CPB is discussed in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/103812.html" rel="external">
          "Management of cardiopulmonary bypass", section on 'Maintenance of anticoagulation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H610016181">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120167.html" rel="external">
          "Society guideline links: Transfusion and patient blood management"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/118172.html" rel="external">
          "Society guideline links: Management of cardiopulmonary bypass"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H117034296">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Effects of cardiopulmonary bypass (CPB)
         </strong>
         –
         <strong>
         </strong>
         Contact of blood with nonendothelial surfaces of the CPB circuit induces an intense inflammatory response resulting in coagulopathy due to platelet activation and dysfunction, initiation of the coagulation cascade, and decreased levels of circulating coagulation factors  (
         <a class="graphic graphic_figure graphicRef120782" href="/z/d/graphic/120782.html" rel="external">
          figure 1
         </a>
         ). Thrombin generation and activation of fibrinolytic pathways result in consumption of platelets and pro- and anticoagulant proteins (especially fibrinogen and antithrombin). Hemodilution and hypothermia may exacerbate coagulopathy after CPB. (See
         <a class="local">
          'Effects of cardiopulmonary bypass on hemostasis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Strategies to conserve blood before CPB
         </strong>
         –
         <strong>
         </strong>
         Blood conservation strategies often used in the prebypass period include aggressive reversal of preoperative anemia with iron supplementation, as indicated, blood salvage technology and, in selected patients, acute normovolemic hemodilution (ANH). (See
         <a class="medical medical_review" href="/z/d/html/7937.html" rel="external">
          "Surgical blood conservation: Intraoperative blood salvage"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7936.html" rel="external">
          "Surgical blood conservation: Acute normovolemic hemodilution"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Strategies to minimize excessive hemodilution
         </strong>
         <strong>
          before and during CPB
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prebypass
         </strong>
         –
         <strong>
         </strong>
         Restriction to the small volumes necessary to administer intravenous (IV) medications in patients who are euvolemic and not undergoing ANH. (See
         <a class="local">
          'Avoiding excessive fluid administration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          During CPB
         </strong>
         –
         <strong>
         </strong>
         Use of minimal CPB circuit prime volume, autologous blood priming (AP) of circuit tubing, and ultrafiltration (UF) techniques. (See
         <a class="local">
          'Strategies to minimize further hemodilution'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of anemia
         </strong>
         –
         <strong>
         </strong>
         During CPB, initial treatment of hemoglobin (Hb) &lt;7.5 g/dL (or hematocrit [Hct] &lt;22 percent) is removal of fluid by UF (hemoconcentration) when possible [
         <a href="#rid59">
          59
         </a>
         ]. Transfusion of packed red blood cells (RBCs) is reasonable if Hb remains &lt;7.5 g/dL during or after CPB when further hemoconcentration is ineffective or not possible. (See
         <a class="local">
          'Management of anemia'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">
          "Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Cardiac surgery'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of anticoagulation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Routine heparin management
         </strong>
         –
         <strong>
         </strong>
         An IV dose of heparin is administered before aortic cannulation, typically 300 to 400 units/kg, and adequate systemic anticoagulation is confirmed to prevent clot formation in the CPB circuit. The degree of thrombin inhibition after heparin administration is measured with point-of-care tests such as activated whole blood clotting time (ACT) to achieve and maintain a targeted value, typically 400 to 480 seconds, before initiation of CPB. (See
         <a class="local">
          'Systemic anticoagulation'
         </a>
         above and
         <a class="local">
          'Maintenance of anticoagulation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Management of heparin resistance
         </strong>
         –
         <strong>
         </strong>
         Management of "heparin resistance" is shown in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef110924" href="/z/d/graphic/110924.html" rel="external">
          algorithm 1
         </a>
         ). In patients who have known or suspected antithrombin (AT) deficiency, we suggest administration of AT concentrate 500 to 1000 units (if available), rather than Fresh Frozen Plasma (FFP) two to four units (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). AT concentrate is preferred to FFP since it does not result in volume overload and there is a lower risk of infection transmission and other complications of blood transfusion. Rarely, a lower ACT value of approximately 350 seconds may be accepted for initiation of CPB in a patient with heparin resistance, with administration of additional heparin by a fixed dosing regimen. (See
         <a class="local">
          'Heparin resistance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Management of heparin-induced thrombocytopenia (HIT)
         </strong>
         –
         <strong>
         </strong>
         Occasionally, a patient presents for cardiac surgery with a current or remote history of HIT  (
         <a class="graphic graphic_algorithm graphicRef118879" href="/z/d/graphic/118879.html" rel="external">
          algorithm 2
         </a>
         ). If HIT antibodies are present, surgery is delayed if possible. Details regarding management of these patients are available in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/118004.html" rel="external">
          "Management of heparin-induced thrombocytopenia (HIT) during cardiac or vascular surgery"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of antifibrinolytic agents
         </strong>
         –
         <strong>
         </strong>
         We administer prophylactic antifibrinolytic therapy (
         <a class="drug drug_general" data-topicid="8561" href="/z/d/drug information/8561.html" rel="external">
          aminocaproic acid
         </a>
         [EACA] or
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          tranexamic acid
         </a>
         [TXA]) before initiation of CPB, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/140949.html" rel="external">
          "Intraoperative use of antifibrinolytic agents", section on 'Use of antifibrinolytic agents in cardiac surgery'
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Sniecinski RM, Chandler WL. Activation of the hemostatic system during cardiopulmonary bypass. Anesth Analg 2011; 113:1319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Despotis GJ, Avidan MS, Hogue CW Jr. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 2001; 72:S1821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warren OJ, Smith AJ, Alexiou C, et al. The inflammatory response to cardiopulmonary bypass: part 1--mechanisms of pathogenesis. J Cardiothorac Vasc Anesth 2009; 23:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barry AE, Chaney MA, London MJ. Anesthetic management during cardiopulmonary bypass: a systematic review. Anesth Analg 2015; 120:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho LTS, Lenihan M, McVey MJ, et al. The association between platelet dysfunction and adverse outcomes in cardiac surgical patients. Anaesthesia 2019; 74:1130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edmunds LH Jr. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1998; 66:S12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 1997; 112:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Day JR, Taylor KM. The systemic inflammatory response syndrome and cardiopulmonary bypass. Int J Surg 2005; 3:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warren OJ, Watret AL, de Wit KL, et al. The inflammatory response to cardiopulmonary bypass: part 2--anti-inflammatory therapeutic strategies. J Cardiothorac Vasc Anesth 2009; 23:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mori M, Zhuo H, Liu F, et al. Predictors of Cardiac Surgery Patients Who Tolerate Blood Conservation in Cardiac Surgery. Ann Thorac Surg 2019; 107:1737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hameed I, Cifu AS, Geirsson A. Blood Management in High-risk Surgery. JAMA 2022; 327:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joshi RV, Wilkey AL, Blackwell JM, et al. Blood Conservation and Hemostasis in Cardiac Surgery: A Survey of Practice Variation and Adoption of Evidence-Based Guidelines. Anesth Analg 2021; 133:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irving AH, Harris A, Petrie D, et al. Impact of patient blood management guidelines on blood transfusions and patient outcomes during cardiac surgery. J Thorac Cardiovasc Surg 2020; 160:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wahba A, Milojevic M, Boer C, et al. 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery. Eur J Cardiothorac Surg 2020; 57:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raphael J, Mazer CD, Subramani S, et al. Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients. Anesth Analg 2019; 129:1209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaller RT Jr, Schaller J, Morgan A, Furman EB. Hemodilution anesthesia: a valuable aid to major cancer surgery in children. Am J Surg 1983; 146:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barile L, Fominskiy E, Di Tomasso N, et al. Acute Normovolemic Hemodilution Reduces Allogeneic Red Blood Cell Transfusion in Cardiac Surgery: A Systematic Review and Meta-analysis of Randomized Trials. Anesth Analg 2017; 124:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stammers AH, Mongero LB, Tesdahl E, et al. The effectiveness of acute normolvolemic hemodilution and autologous prime on intraoperative blood management during cardiac surgery. Perfusion 2017; 32:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lander H, Zammert M, FitzGerald D. Anticoagulation management during cross-clamping and bypass. Best Pract Res Clin Anaesthesiol 2016; 30:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarthy CP, Vaduganathan M, Solomon E, et al. Running thin: implications of a heparin shortage. Lancet 2020; 395:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358:2457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shore-Lesserson L, Baker RA, Ferraris VA, et al. The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines-Anticoagulation During Cardiopulmonary Bypass. Ann Thorac Surg 2018; 105:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shore-Lesserson L, Baker RA, Ferraris VA, et al. The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines-Anticoagulation During Cardiopulmonary Bypass. Anesth Analg 2018; 126:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haas E, Fischer F, Levy F, et al. Identifying optimal heparin management during cardiopulmonary bypass in obese patients: A prospective observational comparative study. Eur J Anaesthesiol 2016; 33:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vienne M, Haas E, Wipf T, et al. Adjusted calculation model of heparin management during cardiopulmonary bypass in obese patients: A randomised controlled trial. Eur J Anaesthesiol 2018; 35:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metz S, Keats AS. Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding. Ann Thorac Surg 1990; 49:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmer K, Ridgway T, Al-Rawi O, Poullis M. Heparin therapy during extracorporeal circulation: deriving an optimal activated clotting time during cardiopulmonary bypass for isolated coronary artery bypass grafting. J Extra Corpor Technol 2012; 44:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finley A, Greenberg C. Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass. Anesth Analg 2013; 116:1210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lobato RL, Despotis GJ, Levy JH, et al. Anticoagulation management during cardiopulmonary bypass: a survey of 54 North American institutions. J Thorac Cardiovasc Surg 2010; 139:1665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avidan MS, Levy JH, Scholz J, et al. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 2005; 102:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawatsu S, Sasaki K, Sakatsume K, et al. Predictors of Heparin Resistance Before Cardiovascular Operations in Adults. Ann Thorac Surg 2018; 105:1316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy JH, Montes F, Szlam F, Hillyer CD. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg 2000; 90:1076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaidan JR, Johnson S, Brynes R, et al. Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery. Anesth Analg 1986; 65:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalter RD, Saul CM, Wetstein L, et al. Cardiopulmonary bypass. Associated hemostatic abnormalities. J Thorac Cardiovasc Surg 1979; 77:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKinney MC, Riley JB. Evidence-based algorithm for heparin dosing before cardiopulmonary bypass. Part 1: Development of the algorithm. J Extra Corpor Technol 2007; 39:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Brown JR, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011; 91:944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sniecinski RM, Bennett-Guerrero E, Shore-Lesserson L. Anticoagulation Management and Heparin Resistance During Cardiopulmonary Bypass: A Survey of Society of Cardiovascular Anesthesiologists Members. Anesth Analg 2019; 129:e41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemmer JH Jr, Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2002; 123:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams MR, D'Ambra AB, Beck JR, et al. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 2000; 70:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanbak M. The treatment of heparin resistance with Antithrombin III in cardiac surgery. Can J Anaesth 1999; 46:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conley JC, Plunkett PF. Antithrombin III in cardiac surgery: an outcome study. J Extra Corpor Technol 1998; 30:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiess BD. Treating heparin resistance with antithrombin or fresh frozen plasma. Ann Thorac Surg 2008; 85:2153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ural K, Owen C. Pro: The Hepcon HMS Should Be Used Instead of Traditional Activated Clotting Time (ACT) to Dose Heparin and Protamine for Cardiac Surgery Requiring Cardiopulmonary Bypass. J Cardiothorac Vasc Anesth 2016; 30:1727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilly G, Trusheim J. Con: The Hepcon HMS Should Not Be Used Instead of Traditional Activated Clotting Time to Dose Heparin and Protamine for Cardiac Surgery Requiring Cardiopulmonary Bypass. J Cardiothorac Vasc Anesth 2016; 30:1730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jooste EH, Scholl R, Wu YH, et al. Double-Blind, Randomized, Placebo-Controlled Trial Comparing the Effects of Antithrombin Versus Placebo on the Coagulation System in Infants with Low Antithrombin Undergoing Congenital Cardiac Surgery. J Cardiothorac Vasc Anesth 2019; 33:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ivascu NS, Fitzgerald M, Ghadimi K, et al. Heparin-Induced Thrombocytopenia: A Review for Cardiac Anesthesiologists and Intensivists. J Cardiothorac Vasc Anesth 2019; 33:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dyke CM, Smedira NG, Koster A, et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 2006; 131:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smedira NG, Dyke CM, Koster A, et al. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 2006; 131:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dyke CM, Aldea G, Koster A, et al. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies. Ann Thorac Surg 2007; 84:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koster A, Faraoni D, Levy JH. Argatroban and Bivalirudin for Perioperative Anticoagulation in Cardiac Surgery. Anesthesiology 2018; 128:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koster A, Dyke CM, Aldea G, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 2007; 83:572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ranucci M, Carboni G, Cotza M, et al. Hemodilution on cardiopulmonary bypass as a determinant of early postoperative hyperlactatemia. PLoS One 2015; 10:e0126939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hensley NB, Gyi R, Zorrilla-Vaca A, et al. Retrograde Autologous Priming in Cardiac Surgery: Results From a Systematic Review and Meta-analysis. Anesth Analg 2021; 132:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phoon PHY, Hwang NC. Conventional Ultrafiltration-No More Role in Elective Adult Cardiac Surgery? J Cardiothorac Vasc Anesth 2021; 35:1319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manning MW, Li YJ, Linder D, et al. Conventional Ultrafiltration During Elective Cardiac Surgery and Postoperative Acute Kidney Injury. J Cardiothorac Vasc Anesth 2021; 35:1310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuntz RA, Holt DW, Turner S, et al. Effects of conventional ultrafiltration on renal performance during adult cardiopulmonary bypass procedures. J Extra Corpor Technol 2006; 38:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heath M, Raghunathan K, Welsby I, Maxwell C. Using Zero Balance Ultrafiltration with Dialysate as a Replacement Fluid for Hyperkalemia during Cardiopulmonary Bypass. J Extra Corpor Technol 2014; 46:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paugh TA, Dickinson TA, Martin JR, et al. Impact of Ultrafiltration on Kidney Injury After Cardiac Surgery: The Michigan Experience. Ann Thorac Surg 2015; 100:1683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Timpa JG, O'Meara LC, Goldberg KG, et al. Implementation of a Multidisciplinary Bleeding and Transfusion Protocol Significantly Decreases Perioperative Blood Product Utilization and Improves Some Bleeding Outcomes. J Extra Corpor Technol 2016; 48:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kandil OA, Motawea KR, Darling E, et al. Ultrafiltration and cardiopulmonary bypass associated acute kidney injury: A systematic review and meta-analysis. Clin Cardiol 2021; 44:1700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazer CD, Whitlock RP, Fergusson DA, et al. Restrictive or liberal red-cell transfusion for cardiac surgery. N Engl J Med 2017; 377:2133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mueller MM, Van Remoortel H, Meybohm P, et al. Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference. JAMA 2019; 321:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hessel EA 2nd. What's New in Cardiopulmonary Bypass. J Cardiothorac Vasc Anesth 2019; 33:2296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scrascia G, Guida P, Rotunno C, et al. Anti-inflammatory strategies to reduce acute kidney injury in cardiac surgery patients: a meta-analysis of randomized controlled trials. Artif Organs 2014; 38:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 2007; 83:S27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel NN, Murphy GJ. Restrictive transfusion practice in cardiac surgery patients is safe, but what transfusion threshold is safe for my patient? Eur Heart J 2019; 40:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeFoe GR, Ross CS, Olmstead EM, et al. Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg 2001; 71:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habib RH, Zacharias A, Schwann TA, et al. Adverse effects of low hematocrit during cardiopulmonary bypass in the adult: should current practice be changed? J Thorac Cardiovasc Surg 2003; 125:1438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karkouti K, Djaiani G, Borger MA, et al. Low hematocrit during cardiopulmonary bypass is associated with increased risk of perioperative stroke in cardiac surgery. Ann Thorac Surg 2005; 80:1381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swaminathan M, Phillips-Bute BG, Conlon PJ, et al. The association of lowest hematocrit during cardiopulmonary bypass with acute renal injury after coronary artery bypass surgery. Ann Thorac Surg 2003; 76:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ranucci M, Baryshnikova E, Ciotti E, et al. Hemodilution on Cardiopulmonary Bypass: Thromboelastography Patterns and Coagulation-Related Outcomes. J Cardiothorac Vasc Anesth 2017; 31:1588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karkouti K, Wijeysundera DN, Yau TM, et al. Acute kidney injury after cardiac surgery: focus on modifiable risk factors. Circulation 2009; 119:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xue FS, Li RP, Sun C. Association Between Acute Kidney Injury and Hemodilution During Cardiopulmonary Bypass. Ann Thorac Surg 2015; 100:1967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ranucci M, Romitti F, Isgrò G, et al. Oxygen delivery during cardiopulmonary bypass and acute renal failure after coronary operations. Ann Thorac Surg 2005; 80:2213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ranucci M, Aloisio T, Carboni G, et al. Acute Kidney Injury and Hemodilution During Cardiopulmonary Bypass: A Changing Scenario. Ann Thorac Surg 2015; 100:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sickeler R, Phillips-Bute B, Kertai MD, et al. The risk of acute kidney injury with co-occurrence of anemia and hypotension during cardiopulmonary bypass relative to anemia alone. Ann Thorac Surg 2014; 97:865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng RR, Chew ST, Liu W, et al. Identification of modifiable risk factors for acute kidney injury after coronary artery bypass graft surgery in an Asian population. J Thorac Cardiovasc Surg 2014; 147:1356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haase M, Bellomo R, Story D, et al. Effect of mean arterial pressure, haemoglobin and blood transfusion during cardiopulmonary bypass on post-operative acute kidney injury. Nephrol Dial Transplant 2012; 27:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habib RH, Zacharias A, Schwann TA, et al. Role of hemodilutional anemia and transfusion during cardiopulmonary bypass in renal injury after coronary revascularization: implications on operative outcome. Crit Care Med 2005; 33:1749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karkouti K, Beattie WS, Wijeysundera DN, et al. Hemodilution during cardiopulmonary bypass is an independent risk factor for acute renal failure in adult cardiac surgery. J Thorac Cardiovasc Surg 2005; 129:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karkouti K, Grocott HP, Hall R, et al. Interrelationship of preoperative anemia, intraoperative anemia, and red blood cell transfusion as potentially modifiable risk factors for acute kidney injury in cardiac surgery: a historical multicentre cohort study. Can J Anaesth 2015; 62:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan UA, Coca SG, Hong K, et al. Blood transfusions are associated with urinary biomarkers of kidney injury in cardiac surgery. J Thorac Cardiovasc Surg 2014; 148:726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clifford L, Jia Q, Subramanian A, et al. Risk Factors and Clinical Outcomes Associated with Perioperative Transfusion-associated Circulatory Overload. Anesthesiology 2017; 126:409.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 94297 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22003219" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Activation of the hemostatic system during cardiopulmonary bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11722116" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Mechanisms and attenuation of hemostatic activation during extracorporeal circulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18930659" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The inflammatory response to cardiopulmonary bypass: part 1--mechanisms of pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25790208" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Anesthetic management during cardiopulmonary bypass: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30932171" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The association between platelet dysfunction and adverse outcomes in cardiac surgical patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9869435" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Inflammatory response to cardiopulmonary bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9315800" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17462274" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The systemic inflammatory response syndrome and cardiopulmonary bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19054695" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The inflammatory response to cardiopulmonary bypass: part 2--anti-inflammatory therapeutic strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30639361" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Predictors of Cardiac Surgery Patients Who Tolerate Blood Conservation in Cardiac Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35133425" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Blood Management in High-risk Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33939648" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Blood Conservation and Hemostasis in Cardiac Surgery: A Survey of Practice Variation and Adoption of Evidence-Based Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31711621" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Impact of patient blood management guidelines on blood transfusions and patient outcomes during cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31576396" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31613811" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6869683" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Hemodilution anesthesia: a valuable aid to major cancer surgery in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27669554" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Acute Normovolemic Hemodilution Reduces Allogeneic Red Blood Cell Transfusion in Cardiac Surgery: A Systematic Review and Meta-analysis of Randomized Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28447921" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The effectiveness of acute normolvolemic hemodilution and autologous prime on intraoperative blood management during cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27650345" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Anticoagulation management during cross-clamping and bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31982034" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Running thin: implications of a heparin shortage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18434646" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Contaminated heparin associated with adverse clinical events and activation of the contact system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29362176" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines-Anticoagulation During Cardiopulmonary Bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29346209" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The Society of Thoracic Surgeons, The Society of Cardiovascular Anesthesiologists, and The American Society of ExtraCorporeal Technology: Clinical Practice Guidelines-Anticoagulation During Cardiopulmonary Bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26886138" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Identifying optimal heparin management during cardiopulmonary bypass in obese patients: A prospective observational comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29521662" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Adjusted calculation model of heparin management during cardiopulmonary bypass in obese patients: A randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2310251" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23198395" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Heparin therapy during extracorporeal circulation: deriving an optimal activated clotting time during cardiopulmonary bypass for isolated coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23408671" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20303507" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Anticoagulation management during cardiopulmonary bypass: a survey of 54 North American institutions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15681940" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29501637" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Predictors of Heparin Resistance Before Cardiovascular Operations in Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10781455" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3954111" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/762986" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Cardiopulmonary bypass. Associated hemostatic abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18293809" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Evidence-based algorithm for heparin dosing before cardiopulmonary bypass. Part 1: Development of the algorithm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21353044" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30540616" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Anticoagulation Management and Heparin Resistance During Cardiopulmonary Bypass: A Survey of Society of Cardiovascular Anesthesiologists Members.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11828278" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11016326" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A randomized trial of antithrombin concentrate for treatment of heparin resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10391608" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The treatment of heparin resistance with Antithrombin III in cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10537578" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Antithrombin III in cardiac surgery: an outcome study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18498854" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Treating heparin resistance with antithrombin or fresh frozen plasma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27641953" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Pro: The Hepcon HMS Should Be Used Instead of Traditional Activated Clotting Time (ACT) to Dose Heparin and Protamine for Cardiac Surgery Requiring Cardiopulmonary Bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27751763" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Con: The Hepcon HMS Should Not Be Used Instead of Traditional Activated Clotting Time to Dose Heparin and Protamine for Cardiac Surgery Requiring Cardiopulmonary Bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30072263" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Double-Blind, Randomized, Placebo-Controlled Trial Comparing the Effects of Antithrombin Versus Placebo on the Coagulation System in Infants with Low Antithrombin Undergoing Congenital Cardiac Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30502310" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Heparin-Induced Thrombocytopenia: A Review for Cardiac Anesthesiologists and Intensivists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16515902" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16515924" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17720385" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29206646" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Argatroban and Bivalirudin for Perioperative Anticoagulation in Cardiac Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17257990" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25992896" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Hemodilution on cardiopulmonary bypass as a determinant of early postoperative hyperlactatemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32947294" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Retrograde Autologous Priming in Cardiac Surgery: Results From a Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33546970" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Conventional Ultrafiltration-No More Role in Elective Adult Cardiac Surgery?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33339661" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Conventional Ultrafiltration During Elective Cardiac Surgery and Postoperative Acute Kidney Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16921688" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Effects of conventional ultrafiltration on renal performance during adult cardiopulmonary bypass procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26357794" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Using Zero Balance Ultrafiltration with Dialysate as a Replacement Fluid for Hyperkalemia during Cardiopulmonary Bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26209495" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Impact of Ultrafiltration on Kidney Injury After Cardiac Surgery: The Michigan Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27134303" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Implementation of a Multidisciplinary Bleeding and Transfusion Protocol Significantly Decreases Perioperative Blood Product Utilization and Improves Some Bleeding Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34837387" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Ultrafiltration and cardiopulmonary bypass associated acute kidney injury: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29130845" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Restrictive or liberal red-cell transfusion for cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30860564" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30928282" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : What's New in Cardiopulmonary Bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23876045" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Anti-inflammatory strategies to reduce acute kidney injury in cardiac surgery patients: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17462454" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30137269" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Restrictive transfusion practice in cardiac surgery patients is safe, but what transfusion threshold is safe for my patient?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11269449" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Northern New England Cardiovascular Disease Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12830066" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Adverse effects of low hematocrit during cardiopulmonary bypass in the adult: should current practice be changed?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16181875" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Low hematocrit during cardiopulmonary bypass is associated with increased risk of perioperative stroke in cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12963200" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : The association of lowest hematocrit during cardiopulmonary bypass with acute renal injury after coronary artery bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28778772" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Hemodilution on Cardiopulmonary Bypass: Thromboelastography Patterns and Coagulation-Related Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19153273" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Acute kidney injury after cardiac surgery: focus on modifiable risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26522555" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Association Between Acute Kidney Injury and Hemodilution During Cardiopulmonary Bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16305874" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Oxygen delivery during cardiopulmonary bypass and acute renal failure after coronary operations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25916873" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Acute Kidney Injury and Hemodilution During Cardiopulmonary Bypass: A Changing Scenario.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24266946" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : The risk of acute kidney injury with co-occurrence of anemia and hypotension during cardiopulmonary bypass relative to anemia alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24183907" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Identification of modifiable risk factors for acute kidney injury after coronary artery bypass graft surgery in an Asian population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21677302" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Effect of mean arterial pressure, haemoglobin and blood transfusion during cardiopulmonary bypass on post-operative acute kidney injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16096452" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Role of hemodilutional anemia and transfusion during cardiopulmonary bypass in renal injury after coronary revascularization: implications on operative outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15678051" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Hemodilution during cardiopulmonary bypass is an independent risk factor for acute renal failure in adult cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25537735" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Interrelationship of preoperative anemia, intraoperative anemia, and red blood cell transfusion as potentially modifiable risk factors for acute kidney injury in cardiac surgery: a historical multicentre cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24820190" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Blood transfusions are associated with urinary biomarkers of kidney injury in cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28072601" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Risk Factors and Clinical Outcomes Associated with Perioperative Transfusion-associated Circulatory Overload.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
